Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meridian Bioscience has received FDA clearance for TRU Legionella, a new rapid assay for detection of legionellosis.
Subscribe to our email newsletter
TRU Legionella provides optimized detection of Legionella pneumophila serogroup 1 that is most commonly associated with Legionnaire’s disease.
TRU Legionella allows the laboratories with a cost effective and rapid result for Legionella detection, the company said.
Legionellosis is characterized by non-specific upper respiratory symptoms.
Meridian Bioscience chief executive officer John Kraeutler said TRU Legionella provides labs with an accurate tool that can speed the detection of an under-diagnosed pathogen enabling rapid treatment for the patient.
"TRU Legionella is in distribution, via Meridian Bioscience Europe, for our European customers," Kraeutler added.